BlackLineの空売り状況は、投資家がBlackLineの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

BlackLine (NASDAQ:BL) 株価情報, 空売り情報

BlackLine

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

BlackLine Inc

BELLEVUE LIFE SCIENCES ACQUISITION CORP COM

BELLEVUE LIFE SCIENCES ACQUISITION CORP RT

BELLEVUE LIFE SCIENCES ACQUISITION CORP UNIT 1 COM & 1 WT & 1 RT EXP

BELLEVUE LIFE SCIENCES ACQUISITION CORP WT EXP

BLUE LAGOON RESOURCES INC by Blue Lagoon Resources Inc.

Blue Lagoon Resources Inc

BlockWallet

Blast - United States Dollar

Blue Bird Corp

Bilibili Inc

BLOOMBERRY RESORTS CORP by Bloomberry Resorts Corp

Bloomberry Resorts Corp

Blackboxstocks Inc

Black Cat Syndicate Ltd

Bellicum Pharmaceuticals Inc

Siren Nasdaq NexGen Economy ETF

Bausch & Lomb Corp

iShares Large Cap Core Active ETF

Bloomzed Loyalty Club Ticket

iShares Large Cap Value Active ETF

TopBuild Corp

Blade Air Mobility, Inc. - Class A Common Stock

Blade Air Mobility Inc

Cambria Global Real Estate ETF

Ballard Power Systems, Inc. - Common Shares

Ballard Power Systems Inc

Builders FirstSource Inc

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

Blackrock Municipal Income Trust II

BRANDED LEGACY INC by BRANDED LEGACY INC.

Branded Legacy Inc

Inspire Global Hope ETF

Bleuacacia Ltd

BLEUACACIA LTD RT

Bleuacacia Ltd Units (1 Ord Share Class A &1Right & 1/2 War)

BELEAVE INC ORD by Beleave Inc.

BALFOUR BEATTY PLC U/ADR by Balfour Beatty Plc

Balfour Beatty PLC

BIOLIFE SCIENCES INC by BIOLIFE SCIENCES INC.

Biolife Sciences Inc

BLUEFIRE EQUIPMENT CORP by BlueFire Equipment Corp.

BlueFire Equipment Corp

BioLife Solutions Inc

Blue Foundry Bancorp

BULIGO CAPITAL LTD by BULIGO CAPITAL LTD.

BAILLIE GIFFORD US GROWTH by BAILLIE GIFFORD US GROWTH TR PLC

BLGI Inc

BioLargo Inc

BELGRAVIA HARTFORD INC by BELGRAVIA HARTFORD CAP INC.

Belgravia Hartford Capital Inc

BALOISE HLDGS BASEL NAMEN by Baloise Holdings AG

Baloise Holding AG

BALOISE HLDGS UNSP/ADR by Baloise Holdings AG

BLUE HOLDINGS INC by Blue Holdings, Inc.

BLUEHARBOR BANK (NC) by BlueHarbor Bank (Mooresville NC)

BlueHarbor Bank

BELIMO HOLDINGS AG NEW by Belimo Holding AG

Belimo Holding AG

BB LIQUIDATING INC A by BB Liquidating Inc.

BB Liquidating Inc

BB LIQUIDATING INC B by BB Liquidating Inc.

Boliden AB

Bridgeline Digital Inc

NAPC Defense Inc

i3 Interactive Inc

BeLive Holdings

BERLI JUCKER PCL UNSP/ADR by Berli Jucker Public Co., Ltd.

Berli Jucker PCL

BlackRock Inc

Blackbaud Inc

Invesco Alerian Galaxy Blockchain Users and Decentralized Commerce ETF

GLOBAL GAMING TECHS by Global Gaming Technologies Corp.

Global Gaming Technologies Corp

BUILD KING HLDGS LTD by Build King Holdings, Ltd.

Build King Holdings Ltd

BLACKLINE SAFETY CORP by Blackline Safety Corp

Blackline Safety Corp

BLACKWELL INTELLIGNCE INC by BLACKWELL INTELLIGENCE INC

Blackwell Intelligence Inc

BELL BUCKLE HLDGS INC by Bell Buckle Holdings, Inc.

Bell Buckle Holdings Inc

JPMorgan Exchange-Traded Fund Trust Sustainable Infrastructure ETF

BELL INDUSTRIES INC by Bell Industries, Inc.

BELL EQUIPMENT LTD ORD by Bell Equipment Ltd.

Bell Equipment Ltd

BIOLIGHT LIFE SCIENCE LTD by BioLight Life Sciences Ltd.

BioLight Life Sciences Ltd

BULLET EXPLORATION INC by BULLET EXPLORATION INC.

80 Mile PLC

BILOXI MARSH LANDS CORP by Biloxi Marsh Lands Corp.

Biloxi Marsh Lands Corp

Blum Holdings Inc

Bloom Health Partners Inc Ordinary Shares

BANK LEUMI LE ISRAEL by Bank Leumi Le Israel

Bank Leumi Le-Israel BM

Bloomin Brands Inc

Bloomios Inc

BALMUDA INC by BALMUDA INC

BLUMETRIC ENVIRONMNTL INC by BluMetric Environmental, Inc.

BluMetric Environmental Inc

BloomZ Inc

Balance Labs Inc

Blend Labs Inc

Beeline Holdings Inc

Blink Charging Co

BLUE NOTE MINING INC NEW by Blue Note Mining Inc.

Blue Note Mining Inc

Blocknet

Amplify Transformational Data Sharing ETF

Bloktopia

CO2 Gro Inc

CANNABIX TECHS INC ORD by Cannabix Technologies Inc.

Cannabix Technologies Inc

BullPerks

BLOK TECHNOLOGIES INC by Blok Technologies Inc.

BLOK Technologies Inc

BLUE LINE PROTECTION GRP by Blue Line Protection Group, Inc.

Blue Line Protection Group Inc

Bellerophon Therapeutics Inc Com (New)

BlockQuarry Corp

Billerud AB

Ecolab Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) shares are trading higher after the company reported&nbsp;a first-quarter&nbsp;sales decline of&nbsp;2%&nbsp;year-on-year (Y/Y) to&nbsp;$3.69 billion,&nbsp;missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45064296/ecolab-delivers-continued-double-digit-eps-growth-reported-diluted-eps-1-41-adjusted-diluted-eps-1" rel="noreferrer noopener">consensus estimate of&nbsp;$3.70 billion</a>.
Organic sales grew&nbsp;3% Y/Y, led by growth in the Institutional &amp; Specialty, Pest Elimination, and Life Sciences segments.
Effective the first quarter, Ecolab reorganized its segment reporting: Global Industrial is now Global Water (including the former Water, Food &amp; Beverage, and Paper segments); Global Institutional &amp; Specialty remains unchanged (with Healthcare moving in); Global Life Sciences became a standalone segment; and Global Pest Elimination remains a standalone segment.
In fixed currency, Global Water sales grew&nbsp;3% Y/Y&nbsp;to&nbsp;$1.80 billion, Global Institutional &amp; Specialty fell 3% Y/Y to&nbsp;$1.41 billion, Global Life Sciences upped 5% Y/Y&nbsp;to&nbsp;$167.0 million&nbsp;and, Global Pest Elimination increased&nbsp;7% Y/Y&nbsp;to&nbsp;$278.1 million.
Adjusted operating income increased&nbsp;8%&nbsp;Y/Y to&nbsp;$589.6 million, with an adjusted operating margin of&nbsp;15.9% vs.&nbsp;14.3% a year ago.
Organic operating margin expanded 190 bps Y/Y to 16.0%, on improved value pricing and productivity.
Adjusted EPS of&nbsp;$1.50 (+12%&nbsp;Y/Y)&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">in line with the consensus estimate</a>.
The company held&nbsp;$1.16 billion&nbsp;in cash and equivalents as of March 31, 2025.
Outlook: Ecolab expects&nbsp;second-quarter&nbsp;adjusted EPS of&nbsp;$1.84-$1.94 (+10% to 15% Y/Y), vs. the&nbsp;$1.91 estimate.
The company reiterated 2025 adjusted EPS at $7.42&nbsp;–&nbsp;$7.62 (+12% to 15%),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">compared to the&nbsp;$7.49&nbsp;estimate</a>.
The company repurchased around 0.6 million shares during the quarter.
Christophe Beck, Ecolab's chairman and chief executive officer, said, &#8221;We expect to deliver continued 12-15% earnings growth this year, even as we face a very unpredictable operating environment with soft end market demand and rapidly changing international trade policy. We are making proactive and strategically consistent adjustments to our delivery path due to these external conditions.&#8221;
&#8221;We look to continue to outperform our end markets as we work to convert our strong new business wins, which all leverage our One Ecolab growth initiative and our record innovation pipeline.&#8221;
&#8221;To overcome the impact from tariffs, we are leveraging the strength of Ecolab&#8217;s world-class supply chain, our ‘local for local&#8217; production model, and our recently announced trade surcharge.&#8221;
Investors can gain exposure to the stock via&nbsp;VanEck Environmental Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVX#NYSE">EVX</a>) and&nbsp;iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>).
Price Action: ECL shares are up 2.3% at $244.51 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44651693/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

News

Guidance

Movers

Market Vectors Environmental Services Index Fund

iShares Trust Dow Jones US Basic Materials Sector Index Fund

Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Market Outperform and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

PRLD

JMP Securities Reiterates Market Outperform on Prelude Therapeutics, Maintains $4 Price Target

Trading Ideas

General

Live On CNBC Josh Brown Announces Sold Some Pfizer

Late last week, Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) reported <a href="https://www.benzinga.com/news/earnings/25/04/44977776/valero-posts-higher-than-expected-profit-despite-sharp-refining-margin-decline">better-than-declined quarterly profits</a>.
So far this year, the company's stock has underperformed its closest peer, Marathon Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) by around 6%. It also underperformed the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) by about 3%, according to Goldman Sachs.
The Valero Energy Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586f95cd72b34c0001c9b160/neil-mehta">Analyst Neil Mehta</a> upgraded the rating from Sell to Neutral, while raising the price target from $115 to $127.
The Valero Energy Thesis: Many of the headwinds that resulted in the stock's underperformance are now reversing, Mehta said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The analyst stated three reasons for the upgrade:
<ul>
<li>Following consensus revisions, expectations better reflect "the deceleration in refining profitability with VLO 2025 EPS having been negatively revised by ~50% over the last year," he said.</li>
<li>The crude environment seems to be improving and the OPEC had begun adding barrels into the market, Mehta mentioned. "We believe the incremental heavy barrels should support more favorable crude differentials and support margins at Valero," he further wrote.</li>
<li>Although the demand environment in uncertain, the supply side is faced with larger refining closures.</li>
</ul>
"We additionally highlight the company's relatively healthy balance sheet and strong cash flow generation which we believe supports the company's continued commitment to shareholder returns," Mehta said.
Price Action: Shares of Valero Energy had risen by 0.32% to $115.14 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

Valero Energy Analyst Is No Longer Bearish: Here Are 3 Reasons Why

JMP Securities analyst Patrick Walravens reiterates Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Market Outperform and maintains $270 price target.

PCTY

JMP Securities Reiterates Market Outperform on Paylocity Holding, Maintains $270 Price Target

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Market Outperform and maintains $28 price target.

KURA

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) has outperformed the market over the past 5 years by 1.63% on an annualized basis producing an average annual return of 15.93%. Currently, American International Gr has a market capitalization of $48.61 billion. 
Buying $1000 In AIG: If an investor had bought $1000 of AIG stock 5 years ago, it would be worth $2,083.69 today based on a price of $81.93 for AIG at the time of writing.
<h3>American International Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745944218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American International Gr Stock In The Last 5 Years

<a href="https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs">https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs</a>

AMZN

"The team that runs our ultra low cost Amazon Haul store considered the idea of listing import charges on certain products. This was never approved and is not going to happen."- Amazon

JMP Securities analyst Steven DeLaney reiterates Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Market Outperform and maintains $15 price target.

FBRT

JMP Securities Reiterates Market Outperform on Franklin BSP Realty Trust, Maintains $15 Price Target

Truist Securities analyst Michael Ciarmoli maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $205 to $209.

Truist Securities Maintains Buy on Woodward, Raises Price Target to $209

Truist Securities analyst Gregory Miller maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and lowers the price target from $22 to $19.

Truist Securities Maintains Buy on OneSpaWorld Hldgs, Lowers Price Target to $19

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $210 to $199.

BIIB

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Zebra Technologies Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock gained on Tuesday after it reported financial results for&nbsp;<a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the </a>first <a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">quarter</a>. Here's what you need to know.
The mobile computing company reported quarterly sales of $1.31 billion, up by 11.3%, beating analyst estimates of $1.29 billion.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" target="_blank" rel="noreferrer noopener">Zebra Tech Q4 Earnings: Revenue Surges 32%, CEO Cites Strong Retail Demand</a>
Zebra reported adjusted earnings of $4.02 per share, exceeding&nbsp;analyst estimates of $3.62.
Zebra's two main business segments also saw substantial growth during the period. The Enterprise Visibility &amp; Mobility segment recorded net sales of $846 million, up 8% from the previous year. The Asset Intelligence &amp; Tracking segment recorded net sales of $462 million, up 17.9% from the previous year.
The consolidated adjusted gross margin increased 150 bps to 49.6%, primarily due to volume leverage and business mix. Adjusted EBITDA margin expanded by 240 bps to 22.3%.
The company said it had $879 million in cash and cash equivalents as of March 29.
CEO Bill Burns said demand trends continued to be positive into the second quarter, and the company left its full-year outlook unchanged, except for the direct cost of tariffs.&nbsp;
Outlook:&nbsp;For the second quarter, Zebra expects sales growth of 4%-7% or $1.25 billion-$1.30 billion versus the&nbsp;$1.28 billion estimate. The company expects adjusted earnings of $3-$3.50 per share <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus estimates of</a> $3.52.
The company reiterated fiscal 2025 net sales growth of 3%-7% or $5.13 billion-$5.33 billion versus the $5.37 billion estimate. It expects adjusted earnings of $13.75-$14.75 (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" rel="noreferrer noopener">prior $14.75-$15.25</a>) per share versus the $15.89 per share estimate.
ZBRA Price Action:&nbsp;Zebra stock is up 6.57% at 259.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" target="_blank" rel="noreferrer noopener">Alibaba Bets Big On AI With New Cloud Tools As Jack Ma Reemerges In Company Comeback</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

ZBRA

Zebra Stock Rises As Strong Retail Demand, Sales Beat Drive Big Quarter, But Tariffs Cloud Full-Year Outlook

JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform and maintains $18 price target.

ENGN

JMP Securities Reiterates Market Outperform on enGene Holdings, Maintains $18 Price Target

B of A Securities analyst Allen Lutz maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and raises the price target from $22 to $26.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $26

B of A Securities analyst Jean Ann maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underperform and raises the price target from $49 to $50.

B of A Securities Maintains Underperform on Cheniere Energy Partners, Raises Price Target to $50

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $46 price target.

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

JMP Securities Reiterates Market Outperform on Broadstone Net Lease, Maintains $21 Price Target

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.58% on an annualized basis producing an average annual return of 11.78%. Currently, AbbVie has a market capitalization of $344.00 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a price of $194.46 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745943312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Citigroup analyst Paul Diamond initiates coverage on Diversified Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) with a Buy rating and announces Price Target of $16.

Comments

BlackLine

空売り

BlackLine (NASDAQ:BL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル